SCHEMBL1086830

SCHEMBL1086830

O=C1OC2(CCN(C(=O)c3ccc(Cl)cc3)CC2)CN1Cc1cccc(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 2/20 0.46
KCNH2 Q12809 2/20 0.46
RIPK1 Q13546 1/20 0.45
GPR183 P32249 3/20 0.45
CHRM2 P08172 2/20 0.45
CHRM3 P20309 2/20 0.45
MGLL Q99685 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 2/20 0.42
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086429 0.90 RIPK1 (0.47) CCR8KCNH2RIPK1CHRM2CHRM3
SCHEMBL1086413 0.88 SMN1; SMN2 (0.44) RIPK1CHRM2CHRM3MGLLSMN1; SMN2
SCHEMBL1086448 0.87 TACR1 (0.40) RIPK1CHRM2CHRM3SMN1; SMN2ALDH1A1
SCHEMBL1086384 0.87 HTT (0.43) RIPK1SMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL1086391 0.86 MEN1 (0.50) RIPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1086067 0.86 MEN1 (0.59) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL1086125 0.85 KDM4E (0.45) RIPK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1086118 0.84 ALDH1A1 (0.47) CHRM2CHRM3SMN1; SMN2ALDH1A1MEN1
SCHEMBL1086302 0.84 MCHR1 (0.48) CCR8KCNH2GPR183SMN1; SMN2ALDH1A1
SCHEMBL1086487 0.84 SIRT2 (0.42) SMN1; SMN2MEN1KMT2ATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP disclosed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC CCR8 635/4885KCNH2 2136/4885RIPK1 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.